|
Malaysia Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
The Malaysia Pharmaceuticals and Healthcare Report
Independent 5-year pharmaceutical and healthcare industry forecasts for Malaysia .
Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the Malaysian pharmaceutical and healthcare industry.
Competitive intelligence, Malaysian pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the Malaysian market.
The Malaysia Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to end- covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments.
Business Monitor International’s Malaysia Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the Malaysian pharmaceutical and healthcare industry.
Key Benefits of Report
- Benchmark BMI’s Independent 5-year Pharmaceutical and Healthcare Industry Forecasts on Malaysia to test other views – a key input for successful budgeting and strategic business planning in the Malaysian pharmaceutical and healthcare market.
- Target Business Opportunities & Risks in the Malaysian Pharmaceutical and Healthcare Sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Malaysia .
- Exploit The Latest Competitive Malaysian Pharmaceutical and Healthcare Intelligence & company SWOTS on your competitors and peers through company rankings by sales, market share and ownership structure – includes multi-national and national companies in Malaysia .
Coverage
Executive Summary & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI’s forecast analysis, and taken together with BMI’s Economic and Business Environment SWOTS, give a complete overview of market climate.
Market Summary
Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.
Regulatory Regime
Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.
Industry Developments
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.
BMI 5-Year Industry Forecast
5-Year Forecasts to end- for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
- Drug market expenditure (US$bn); drug expenditure per capita (US$); as % of gdp
- Prescription drug market (US$bn)/as % of total market; sales by alimentary tract/metabolism; antibiotics, cardiovascular, central nervous system, oncology, musculoskeletal and respiratory system
- OTC market (US$bn)/as % of total market (sales by analgesic, cough and cold, digestives, skin treatments, vitamins and minerals)
- Generics market (US$bn)/ as % of total market
- Health expenditure (US$bn, % of gdp and per capita); public sector health expenditure as % of total; number of hospitals; beds, hospital admissions, doctors, births and deaths per 000 population
Forecasts based on bespoke BMI economic modelling, using historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.
BMI 5-Year Macroeconomic Forecasts
BMI forecasts for all headline macroeconomic indicators, including:
Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt
Competitive Landscape & Profiles
Intelligence on the market position of major MNC power houses and indigenous companies. BMI profiles key research-based companies. Company SWOTS are provided for all key strategic players, complete with a company activity overview, its leading products and analysis of business opportunities.
|
Malaysia Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Chapter - Executive Summary |
| Malaysia Pharmaceuticals And Healthcare Industry SWOT |
| Malaysia Political SWOT |
| Malaysia Economic SWOT |
| Malaysia Business Environment SWOT |
Chapter - Pharmaceutical Business Environment Ratings |
| Table: Asia Pacific Business Environment Rankings For Q209 |
| Limits Of Potential Returns |
| Risks To Realisation Of Returns |
Chapter - Malaysia: Market Summary |
| Regulatory Regime |
| Pharmaceutical And Medical Advertising |
| Recent Regulatory Developments |
| Intellectual Property Regime |
| Counterfeit Pharmaceuticals |
| Compulsory Licensing |
| Free Trade Agreements |
| Pricing And Reimbursement |
Chapter - Industry Trends And Developments |
| Epidemiology |
| Table: 10 Leading Causes Of Death In Ministry of Health Hospitals, 2005 |
| Healthcare Sector |
| Healthcare Sector Funding |
| Recent Healthcare Sector Developments |
| Pharmaceutical Sector |
| Table: BMI's Crisis Recovery Rating – Malaysia |
| Pharmaceutical Demand |
| Domestic Company Activity |
| Halal Medicine |
| Traditional Medicine |
| Biotechnology And Research |
| Table: Key Points Of The Malaysian National Biotechnology Policy |
| Table: The Benefits Of Conducting Biotechnology Research In Malaysia |
| Recent Biotechnology Developments |
| Tables: Examples Of Pharmaceuticals From Natural Sources |
| Clinical Trials |
| Medical Devices |
| Table: Malaysia – Clinical Diagnostics Market, 2006 (US$mn) |
| Leading Medical Device Players |
| Recent Developments In The Medical Devices Industry |
Chapter - Industry Forecast Scenario |
| Overall Market Forecast |
| Table: Malaysia – Drug Expenditure Indicators, , 2003-2013 |
| Key Growth Factors – Industry |
| Table: Malaysia – Health Expenditure Indicators, 2003-2013 |
| Key Growth Factors – Macroeconomic |
| Table: Malaysia – Economic Activity, 2005-2013 |
| Prescription Market Forecast |
| Table: Malaysia – Prescription Market Indicators, Historical Data And Forecasts (MYRmn unless otherwise stated) |
| Patented Market Forecast |
| Table: Malaysia – Patented Drug Market Indicators, 2003-2013 |
| Generic Drug Market Forecast |
| Table: Malaysia – Generics Drugs Market Indicators, 2003-2013 |
| OTC Market Forecast |
| Table: Malaysia – OTC Drug Market Indicators, 2003-2013 (MYRmn unless otherwise stated) |
| Pharmaceutical Trade Forecast |
| Table: Malaysia – Pharmaceutical Trade Indicators, 2003-2013 (US$mn) |
| Other Healthcare Data Forecasts |
| Table: Malaysia – Other Healthcare Indicators, 2003-2013 |
| Key Risks To BMI's Forecast Scenario |
Chapter - Competitive Landscape |
| Table: Malaysia Pharmaceutical Market, Q406 |
| Table: Malaysia – Leading Firms By 2005 Sales |
| Table: Malaysia – Estimated Spending On Leading 20 Drugs, 2004 |
Chapter - Company Profiles |
| Multinational Companies |
| GlaxoSmithKline (GSK) |
| Pfizer |
| Novartis |
| Merck & Co |
| Sanofi-Aventis |
| Ranbaxy Malaysia |
| Eli Lilly Malaysia |
| Leading Indigenous Manufacturers |
| Pharmaniaga |
| Asia Pharmaceutical Products (APP) |
| Prime Pharmaceutical |
| Bumimedic |
| Hovid |
| Chemical Company of Malaysia (CCM) |
| Kotra Pharma |
| YSP Southeast Holding |
Chapter - Country Snapshot: Malaysia Demographic Data |
| Section 1: Population |
| Table: Demographic Indicators, 2005-2030 |
| Table: Rural/Urban Breakdown, 2005-2030 |
| Section 2: Education And Healthcare |
| Table: Education, 2000-2003 |
| Table: Vital Statistics, 2005-2030 |
| Section 3: Labour Market And Spending Power |
| Table: Employment Indicators, 2001-2006 |
| Table: Consumer Expenditure, 2000-2012 (US$) |
| Table: Average Annual Manufacturing Wages, 2000-2012 |
Chapter - BMI Forecast Modelling |
| How We Generate Our Pharmaceutical Industry Forecasts |
| Pharmaceutical Business Environment Ratings Methodology |
| Ratings Overview |
| Table: Pharmaceutical Business Environment Indicators |
| Weighting |
| Table: Weighting Of Components |
| Sources |
|
Malaysia Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
In the BMI Business Environment Ranking matrix for Q209, Malaysia returned to eight position (from tenth previously), out of the 15 key regional markets surveyed in the Asia Pacific region. Key attractions of the Malaysian pharmaceutical market are the government’s encouragement of the biotechnology sector and the forecast strong annual growth in the country’s pharmaceutical market, which is expected to develop at a compound annual growth rate (GAGR) of 11.85% in local currency terms. Consequently, from being worth around MYR3.29bn (US$0.97bn) in 2008, the consumer value of market is expected to increase to MYR5.75bn (US$1.89bn) in 2013. However, given that per capita pharmaceutical consumption is quite low, especially due to the high out-of-pocket payment levels, patented medicines are likely to grow at a slower pace than generics, despite regulatory improvements targeting the considerable counterfeit activity in the country. In the meantime, the Malaysian economy expanded by a mere 0.1% in Q408, increasing fears that an outright recession may be on the cards in 2009, which also threatens out-of-pocket payments for healthcare and pharmaceuticals.
Nevertheless, the demand for chronic and long-term treatments will continue to rise, given improved survival rates and the slowly ageing population. According to the February 2009 statement by the Health Minister, some 43% of all Malaysians aged 30 or above are at risk of hypertension, with estimates suggesting that some 4.8mn Malaysians are already affected by the condition. Around the same time, the Public Health Medicine Specialist Association of Malaysia began a year-long study into the financial burden of cervical cancer in the country, which is supported by the local subsidiary of the major UK-based drugmaker GlaxoSmithKline (GSK). The research will assess the current costs of human papilloma virus (HPV)-related cervical cancer, while also give costs of the national HPV vaccination programme, which would provide a considerable boost to HPV vaccine manufacturers.
In terms of company news, one of leading local drugmakers, YSP Southeast Asia Holding, maintained expectations of a robust financial trajectory, despite the global economic downturn. The company stated that its focus on prescription drugs, after-sales service and strong branding in the generics sector will ensure profit growth in 2009. Foreign companies are also predicting growth of the generics sector, with US-based generics specialist SOHM Inc. recently expanding its distribution to South East Asia, including Malaysia, Thailand.
Similarly, the research and development (R&D) sector in Malaysia has welcomed the news that Swiss pharmaceutical major Novartis plans to search the rich ecology of the Malaysian state of Sarawak for new medicines. Given the rewards on offer and the drop in productivity from synthetic drug discovery, other innovative pharmaceutical companies are likely to engage in similar activities. Malaysia’s destination for R&D investment is considerable, given its excellent infrastructure, a business-friendly government, and a welleducated, English-speaking population.
|
Malaysia Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Africa |
| Algeria, Egypt, Kenya, Morocco, Nigeria, South Africa and Zimbabwe |
Asia |
| Australia, Bangladesh, China, Hong Kong, India, Indonesia, Japan, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam |
Caribbean |
| Puerto Rico |
Europe |
| Belarus, Belgium, Bulgaria, Croatia, Czech Republic, Estonia, France, Germany, Greece, Hungary, Italy, Kazakhstan, Latvia, Lithuania, Moldova, Netherlands, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Switzerland, Ukraine, United Kingdom and Uzbekistan |
Latin America |
| Argentina, Brazil, Chile, Colombia, Mexico, Peru and Venezuela |
Middle East |
| Bahrain, Iran, Israel, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Turkey and United Arab Emirates |
North America |
| Canada and United States |
Business Monitor InternationalA Market Leader in Country Risk, Industry Intelligence and Company Research Mermaid House, 2 Puddle Dock, Blackfriars, London EC4V 3DS, UK |
BUSINESS MONITOR INTERNATIONAL's country risk analysis and forecasts, market research on leading industries, and multinational company research is relied upon by corporates, banks, government departments and multilateral organisations in over 125 countries around the world. Country Risk Analysis and Forecasts Industry Intelligence and Market Research Company Research |